Company: AGIO
Filing Date: 2025-02-13
Form Type: 10-K
Source: 0001439222-25-000009
Chunk: 702

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-02-13
Form: 10-K
Item: Item 1A
Chunk 702
---
6 million in research and development expenses, which is described below under Research and Development Expenses. 

Research and Development Expenses

Our research and development expenses, by major program, are outlined in the table below: (In thousands)202420232022PK activator (PYRUKYND®)$112,720 $101,322 $83,271 Novel PK activator (tebapivat)14,544 18,267 15,747 In-process research and development— 17,500 — Other research and platform programs20,730 11,492 26,837 Total direct research and development expenses147,994 148,581 125,855 Compensation and related expenses114,618 108,484 109,248 Facilities and IT related expenses & other38,674 38,461 43,290 Other expenses - transition services— — 1,517 Total indirect research and development expenses153,292 146,945 154,055 Total research and development expense$301,286 $295,526 $279,910 

Total Research and Development Expenses – 2024 vs. 2023 – The increase in research and development expenses of $5.8 million in 2024 compared to 2023 was due to a $6.3 million increase in our indirect expenses, partially offset by a $0.6 million decrease in our direct expenses. The increase in indirect expenses was primarily due to a $6.1 million increase in compensation and related expenses due to an increase in workforce related expenses. The decrease in direct expenses was due to the $17.5 million up-front payment in 2023 associated with the Alnylam license agreement discussed above under Overview 

77

and a decrease of $3.7 million in tebapivat costs due to decreased costs associated with clinical trials of tebapivat in patients with SCD and MDS, offset by an $11.4 million increase in PYRUKYND® costs and a $9.2 million increase in other research and platform programs. The increase in PYRUKYND® costs was primarily due to increased process development expenses and increased costs associated with clinical trials for patients with SCD, partially offset by lower costs associated with the phase 3 clinical trials of PYRUKYND® in patients with thalassemia, ENERGIZE and ENERGIZE